{"id":"trastuzumab-plus-pertuzumab-combination","safety":{"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"60.3%","placeboRate":"","totalAtRisk":4201,"totalAffected":2532,"trialsReporting":9},{"effect":"Nausea","drugRate":"47.7%","placeboRate":"","totalAtRisk":4201,"totalAffected":2003,"trialsReporting":9},{"effect":"Alopecia","drugRate":"46.0%","placeboRate":"","totalAtRisk":4201,"totalAffected":1934,"trialsReporting":9},{"effect":"DIARRHOEA","drugRate":"70.5%","placeboRate":"","totalAtRisk":2364,"totalAffected":1667,"trialsReporting":1},{"effect":"NAUSEA","drugRate":"69.3%","placeboRate":"","totalAtRisk":2364,"totalAffected":1639,"trialsReporting":1},{"effect":"ALOPECIA","drugRate":"67.4%","placeboRate":"","totalAtRisk":2364,"totalAffected":1594,"trialsReporting":1},{"effect":"Fatigue","drugRate":"34.1%","placeboRate":"","totalAtRisk":4201,"totalAffected":1432,"trialsReporting":9},{"effect":"FATIGUE","drugRate":"49.1%","placeboRate":"","totalAtRisk":2364,"totalAffected":1160,"trialsReporting":1},{"effect":"Anaemia","drugRate":"25.4%","placeboRate":"","totalAtRisk":4201,"totalAffected":1067,"trialsReporting":9},{"effect":"Vomiting","drugRate":"24.8%","placeboRate":"","totalAtRisk":4201,"totalAffected":1042,"trialsReporting":9},{"effect":"Neutropenia","drugRate":"23.3%","placeboRate":"","totalAtRisk":4201,"totalAffected":980,"trialsReporting":9},{"effect":"Asthenia","drugRate":"23.2%","placeboRate":"","totalAtRisk":4201,"totalAffected":974,"trialsReporting":9},{"effect":"Arthralgia","drugRate":"24.8%","placeboRate":"","totalAtRisk":3816,"totalAffected":946,"trialsReporting":8},{"effect":"Decreased appetite","drugRate":"23.6%","placeboRate":"","totalAtRisk":3983,"totalAffected":940,"trialsReporting":8},{"effect":"Rash","drugRate":"21.7%","placeboRate":"","totalAtRisk":4201,"totalAffected":912,"trialsReporting":9},{"effect":"Constipation","drugRate":"20.5%","placeboRate":"","totalAtRisk":4201,"totalAffected":861,"trialsReporting":9},{"effect":"Headache","drugRate":"21.7%","placeboRate":"","totalAtRisk":3816,"totalAffected":828,"trialsReporting":8},{"effect":"Stomatitis","drugRate":"20.4%","placeboRate":"","totalAtRisk":3889,"totalAffected":792,"trialsReporting":8},{"effect":"VOMITING","drugRate":"32.6%","placeboRate":"","totalAtRisk":2364,"totalAffected":771,"trialsReporting":1},{"effect":"ARTHRALGIA","drugRate":"32.4%","placeboRate":"","totalAtRisk":2364,"totalAffected":765,"trialsReporting":1},{"effect":"Neuropathy peripheral","drugRate":"19.0%","placeboRate":"","totalAtRisk":3983,"totalAffected":756,"trialsReporting":8},{"effect":"Myalgia","drugRate":"18.8%","placeboRate":"","totalAtRisk":3816,"totalAffected":717,"trialsReporting":8},{"effect":"Pyrexia","drugRate":"16.7%","placeboRate":"","totalAtRisk":4201,"totalAffected":700,"trialsReporting":9},{"effect":"CONSTIPATION","drugRate":"29.3%","placeboRate":"","totalAtRisk":2364,"totalAffected":692,"trialsReporting":1},{"effect":"ANAEMIA","drugRate":"28.2%","placeboRate":"","totalAtRisk":2364,"totalAffected":667,"trialsReporting":1},{"effect":"STOMATITIS","drugRate":"28.2%","placeboRate":"","totalAtRisk":2364,"totalAffected":666,"trialsReporting":1},{"effect":"Cough","drugRate":"15.5%","placeboRate":"","totalAtRisk":4201,"totalAffected":653,"trialsReporting":9},{"effect":"Pruritus","drugRate":"15.2%","placeboRate":"","totalAtRisk":4201,"totalAffected":637,"trialsReporting":9},{"effect":"Mucosal inflammation","drugRate":"17.0%","placeboRate":"","totalAtRisk":3671,"totalAffected":623,"trialsReporting":7},{"effect":"MYALGIA","drugRate":"26.2%","placeboRate":"","totalAtRisk":2364,"totalAffected":620,"trialsReporting":1},{"effect":"RASH","drugRate":"26.1%","placeboRate":"","totalAtRisk":2364,"totalAffected":618,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"15.4%","placeboRate":"","totalAtRisk":3983,"totalAffected":614,"trialsReporting":8},{"effect":"Epistaxis","drugRate":"17.0%","placeboRate":"","totalAtRisk":3504,"totalAffected":594,"trialsReporting":7},{"effect":"NEUTROPENIA","drugRate":"25.0%","placeboRate":"","totalAtRisk":2364,"totalAffected":592,"trialsReporting":1},{"effect":"DECREASED APPETITE","drugRate":"24.1%","placeboRate":"","totalAtRisk":2364,"totalAffected":570,"trialsReporting":1},{"effect":"Peripheral sensory neuropathy","drugRate":"14.2%","placeboRate":"","totalAtRisk":3983,"totalAffected":567,"trialsReporting":8},{"effect":"MUCOSAL INFLAMMATION","drugRate":"23.5%","placeboRate":"","totalAtRisk":2364,"totalAffected":555,"trialsReporting":1},{"effect":"HEADACHE","drugRate":"22.8%","placeboRate":"","totalAtRisk":2364,"totalAffected":539,"trialsReporting":1},{"effect":"Insomnia","drugRate":"12.6%","placeboRate":"","totalAtRisk":4201,"totalAffected":530,"trialsReporting":9},{"effect":"ASTHENIA","drugRate":"21.8%","placeboRate":"","totalAtRisk":2364,"totalAffected":515,"trialsReporting":1},{"effect":"HOT FLUSH","drugRate":"20.8%","placeboRate":"","totalAtRisk":2364,"totalAffected":492,"trialsReporting":1},{"effect":"Dizziness","drugRate":"11.6%","placeboRate":"","totalAtRisk":4201,"totalAffected":487,"trialsReporting":9},{"effect":"Nasopharyngitis","drugRate":"13.2%","placeboRate":"","totalAtRisk":3671,"totalAffected":486,"trialsReporting":7},{"effect":"Dysgeusia","drugRate":"13.2%","placeboRate":"","totalAtRisk":3671,"totalAffected":483,"trialsReporting":7},{"effect":"Back pain","drugRate":"12.9%","placeboRate":"","totalAtRisk":3598,"totalAffected":465,"trialsReporting":7},{"effect":"Abdominal pain","drugRate":"11.5%","placeboRate":"","totalAtRisk":3983,"totalAffected":458,"trialsReporting":8},{"effect":"PYREXIA","drugRate":"19.2%","placeboRate":"","totalAtRisk":2364,"totalAffected":455,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"12.3%","placeboRate":"","totalAtRisk":3598,"totalAffected":443,"trialsReporting":7},{"effect":"Dyspnoea","drugRate":"10.4%","placeboRate":"","totalAtRisk":4201,"totalAffected":435,"trialsReporting":9},{"effect":"EPISTAXIS","drugRate":"18.3%","placeboRate":"","totalAtRisk":2364,"totalAffected":433,"trialsReporting":1}]},"_chembl":{"chemblId":"CHEMBL2007641","moleculeType":"Antibody"},"allNames":"trastuzumab plus pertuzumab (combination)","_dailymed":null,"mechanism":{"target":"HER2","drugClass":"HER2 inhibitors","explanation":"This combination therapy uses two monoclonal antibodies, trastuzumab and pertuzumab, which bind to different parts of the HER2 receptor. By doing so, they prevent cancer cells from receiving growth signals, slowing or stopping tumor progression.","oneSentence":"Trastuzumab and pertuzumab target HER2 receptors to block signal transduction pathways, inhibiting tumor growth in HER2-positive cancers."},"_scrapedAt":"2026-03-28T01:47:48.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:46:42.994687+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT07371585","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2026-02-18","conditions":"Breast Cancer Stage IV","enrollment":300},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT04253561","phase":"PHASE1","title":"Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-02-25","conditions":"Metastatic Breast Cancer","enrollment":17},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT07102381","phase":"PHASE2","title":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-09-24","conditions":"HER2-positive Breast Cancer, Breast Cancer","enrollment":125},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT07377643","phase":"PHASE3","title":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-02-10","conditions":"HER2-positive Breast Cancer","enrollment":540},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07416409","phase":"","title":"Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Deraya University","startDate":"2023-06-10","conditions":"Breast Neoplasms, Oncology, HER2-positive Breast Cancer","enrollment":80},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02320435","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-02-02","conditions":"Solid Tumors","enrollment":154},{"nctId":"NCT03101748","phase":"PHASE1, PHASE2","title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-19","conditions":"Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":34},{"nctId":"NCT07402473","phase":"PHASE2","title":"EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-03-01","conditions":"HER2-positive Early-stage Breast Cancer","enrollment":50},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT01796197","phase":"PHASE2","title":"Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-08","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT04208178","phase":"PHASE3","title":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-16","conditions":"Advanced HER2+Breast Cancer","enrollment":19},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":"Breast Neoplasms","enrollment":198},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT06949410","phase":"PHASE1","title":"HER2 Vaccine for Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Pravin T.P Kaumaya","startDate":"2026-03","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":36},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT07299890","phase":"PHASE2","title":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07294534","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-01-27","conditions":"HER2 + Breast Cancer","enrollment":817},{"nctId":"NCT07290166","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-31","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT05786716","phase":"PHASE2, PHASE3","title":"DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations","status":"RECRUITING","sponsor":"Cancer Research UK","startDate":"2023-03-07","conditions":"Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm","enrollment":30},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT07245797","phase":"PHASE2","title":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC","status":"NOT_YET_RECRUITING","sponsor":"Zhimin Shao","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":164},{"nctId":"NCT05722886","phase":"PHASE2, PHASE3","title":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","status":"RECRUITING","sponsor":"Cancer Research UK","startDate":"2023-03-01","conditions":"Haematological Malignancy, Solid Tumour","enrollment":825},{"nctId":"NCT04514419","phase":"PHASE3","title":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2020-06-28","conditions":"Breast Cancer","enrollment":408},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT05954143","phase":"PHASE2","title":"Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bolt Biotherapeutics, Inc.","startDate":"2023-11-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":11},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT06884254","phase":"PHASE3","title":"Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.","status":"WITHDRAWN","sponsor":"EirGenix, Inc.","startDate":"2025-05","conditions":"Early Breast Cancer","enrollment":""},{"nctId":"NCT04108858","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":2},{"nctId":"NCT03264547","phase":"PHASE3","title":"A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2017-08-28","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT05760612","phase":"PHASE3","title":"Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-03-14","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab","enrollment":300},{"nctId":"NCT05385705","phase":"PHASE1","title":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2022-05-11","conditions":"Breast Neoplasms","enrollment":2},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07166185","phase":"","title":"Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Blida 1 University","startDate":"2025-03-01","conditions":"Non Metastatic HER2 Positive Breast Cancer","enrollment":70},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT06414733","phase":"PHASE1","title":"HER-2 B Cell Peptide Vaccine","status":"RECRUITING","sponsor":"Pravin T.P Kaumaya","startDate":"2025-01-17","conditions":"Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT07140393","phase":"PHASE1, PHASE2","title":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10","conditions":"Solid Tumor","enrollment":120},{"nctId":"NCT07129018","phase":"PHASE2","title":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11","conditions":"Biliary Tract Cancer (BTC), First-line Therapy","enrollment":63},{"nctId":"NCT07115095","phase":"NA","title":"Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Nanlin Li","startDate":"2021-01-01","conditions":"HER2-positive Breast Cancer","enrollment":98},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT04740918","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-07","conditions":"Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT07108127","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-20","conditions":"Rectal Cancer, HER2-positive","enrollment":24},{"nctId":"NCT06973525","phase":"PHASE2","title":"This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-01","conditions":"HER2-positive Breast Cancer","enrollment":30},{"nctId":"NCT07093931","phase":"PHASE4","title":"Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-08-01","conditions":"Breast Cancer","enrollment":468},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT03414658","phase":"PHASE2","title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2018-06-21","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT06927180","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-16","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT05346224","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-04-25","conditions":"Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer","enrollment":900},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05838066","phase":"PHASE3","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2023-07-23","conditions":"First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer","enrollment":880},{"nctId":"NCT06190600","phase":"NA","title":"Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Greater Poland Cancer Centre","startDate":"2018-10-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06747338","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-12-16","conditions":"Early or Locally Advanced HER2-positive Breast Cancer","enrollment":520},{"nctId":"NCT04680442","phase":"PHASE2","title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-01","conditions":"Breast Cancer, Heart Failure","enrollment":130},{"nctId":"NCT03417544","phase":"PHASE2","title":"Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nancy Lin, MD","startDate":"2018-05-21","conditions":"HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases","enrollment":19},{"nctId":"NCT06907082","phase":"NA","title":"Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2020-12-28","conditions":"Breast Cancer","enrollment":106},{"nctId":"NCT03820141","phase":"PHASE2","title":"Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-03-03","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT02326974","phase":"PHASE2","title":"T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer","enrollment":164},{"nctId":"NCT04246671","phase":"PHASE1","title":"TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2020-08-10","conditions":"Chordoma, HER2-positive Breast Cancer","enrollment":37},{"nctId":"NCT01817452","phase":"PHASE2","title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2014-03","conditions":"Breast Cancer","enrollment":220},{"nctId":"NCT06835348","phase":"","title":"An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID Study","status":"COMPLETED","sponsor":"Fondazione Oncotech","startDate":"2023-10-03","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05306041","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2023-01-02","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT03125928","phase":"PHASE2","title":"Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2017-06-13","conditions":"HER2-positive Breast Cancer","enrollment":16},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT06754059","phase":"","title":"Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC","status":"RECRUITING","sponsor":"zhangjie","startDate":"2021-06-01","conditions":"HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT06276868","phase":"PHASE2","title":"Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-20","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":71},{"nctId":"NCT03644186","phase":"PHASE2","title":"To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-16","conditions":"Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer","enrollment":147},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT06722599","phase":"","title":"Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients","status":"RECRUITING","sponsor":"Shu Wang","startDate":"2019-01-01","conditions":"HER2-positive Breast Cancer","enrollment":171},{"nctId":"NCT06722612","phase":"","title":"Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer","status":"RECRUITING","sponsor":"Shu Wang","startDate":"2019-01-01","conditions":"HER2-positive Breast Cancer","enrollment":2916},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT06711068","phase":"","title":"Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy","status":"RECRUITING","sponsor":"Shu Wang","startDate":"2019-01-01","conditions":"HER2-positive Breast Cancer","enrollment":8077},{"nctId":"NCT05891561","phase":"PHASE2","title":"Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-11-01","conditions":"Breast Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Trastuzumab plus Pertuzumab (combination)","genericName":"trastuzumab-plus-pertuzumab-combination","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"Trastuzumab plus Pertuzumab is a combination used to treat inoperable, locally advanced or metastatic, ER-positive breast cancer and advanced HER2-positive breast cancer. This combination works by inhibiting the receptor protein-tyrosine kinase erbB-2, a target of the antibody Pertuzumab.","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":21,"withResults":16},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:46:42.994687+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}